Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deutetrabenazine - Teva Pharmaceutical

Drug Profile

Deutetrabenazine - Teva Pharmaceutical

Alternative Names: AUSTEDO; d6-tetrabenazine; Deuterium-substituted tetrabenazine; Dutetrabenazine; SD-809; SD-809 ER; SD-809 Extended Release; TEV-50717

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer Auspex Pharmaceuticals; Nuvelution Pharma; Teva Pharmaceutical Industries
  • Class Antipsychotics; Neuroprotectants; Organic deuterium compounds; Quinolizines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; Dopamine release inhibitors; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Gilles de la Tourette's syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chorea; Drug-induced dyskinesia
  • Phase III Dyskinesias; Gilles de la Tourette's syndrome

Most Recent Events

  • 14 Jun 2019 Phase-III clinical trials in Dyskinesias (In children, In adolescents) in USA (PO) (NCT03813238)
  • 10 Jun 2019 Phase-III clinical trials in Dyskinesias (In adolescents, In children) in Spain (PO) (EudraCT2018-003742-17)
  • 18 May 2019 Updated efficacy and adverse events data from the phase III open-label extension trial in Tardive dyskinesia presented at the 172nd Annual Meeting of the American Psychiatric Association (APA-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top